Literature DB >> 12140134

Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark.

Halla Skuladottir1, Fred R Hirsch, Heine H Hansen, Jørgen H Olsen.   

Abstract

Pulmonary neuroendocrine tumors are currently considered to consist of three grades of malignancy, ranging from typical and atypical carcinoids to large-cell neuroendocrine carcinoma and small-cell carcinoma. The study reported here is the first population-based study of the demographics of patients with neuroendocrine tumors grouped by histological subtype. A cancer registry-based analysis of patients in Denmark in whom bronchial neuroendocrine tumor was diagnosed in 1978-97 was performed and the patients were followed up to 31 December 1999. Typical carcinoid was diagnosed in 105 patients, atypical carcinoid in 192, large-cell neuroendocrine carcinoma in 50 and small-cell carcinoma in 11,998. The recorded incidence of neuroendocrine tumors other than small-cell carcinoma increased by twofold among men (from 0.24 to 0.53 per 100,000 inhabitants per year) and by threefold in women (from 0.14 to 0.41 per 100,000 inhabitants per year) during the study period, while the incidence of small-cell carcinoma decreased among men and levelled off among women. The prognosis of patients with bronchial neuroendocrine tumors varied with the degree of malignancy; the 5-year survival rate ranged from 87% for patients with typical carcinoids, to 44, 15 and 2% for patients with atypical carcinoids, large-cell neuroendocrine carcinoma and small-cell carcinoma, respectively. In Denmark, the incidence of neuroendocrine tumours is increasing. Our findings support the pathological categorization of neuroendocrine tumors into three grades of malignancy. More research is needed to establish the etiological factors in the development of pulmonary neuroendocrine tumors.

Entities:  

Mesh:

Year:  2002        PMID: 12140134     DOI: 10.1016/s0169-5002(02)00080-6

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  34 in total

1.  [Neuroendocrine carcinoma of the lung: a diagnostic and therapeutic challenge].

Authors:  Claudia Böttger; Arne Warth; Peter P Nawroth; Berend Isermann
Journal:  Med Klin (Munich)       Date:  2010-04

2.  Low risk for all-cause mortality among patients with lung neuroendocrine tumors co-diagnosed with pituitary adenomas.

Authors:  Naama Peltz-Sinvani; Ruth Percik; Inbal Uri; Sapir Kon Kfir; Amir Tirosh; Amit Tirosh
Journal:  Endocrine       Date:  2021-05-12       Impact factor: 3.633

3.  Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung.

Authors:  Rania G Aly; Natasha Rekhtman; Xiaoyu Li; Yusuke Takahashi; Takashi Eguchi; Kay See Tan; Charles M Rudin; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2019-05-20       Impact factor: 15.609

4.  Spread through air spaces (STAS) is a predictor of poor outcome in atypical carcinoids of the lung.

Authors:  Serdar Altinay; Jasna Metovic; Federica Massa; Gaia Gatti; Paola Cassoni; Giorgio Vittorio Scagliotti; Marco Volante; Mauro Papotti
Journal:  Virchows Arch       Date:  2019-06-15       Impact factor: 4.064

5.  A Single Center Experience of Feasibility of a Novel Self-Expanding Metallic Airway Stent (Bonastent): A Case Series.

Authors:  Priyanka Makkar; Alberto Revelo; Robert Lee; Mohit Chawla
Journal:  J Bronchology Interv Pulmonol       Date:  2019-10

6.  Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach.

Authors:  Tina Zahel; Sabine Krysa; Esther Herpel; Albrecht Stenzinger; Benjamin Goeppert; Peter Schirmacher; Hans Hoffmann; Philipp A Schnabel; Arne Warth
Journal:  Virchows Arch       Date:  2012-03       Impact factor: 4.064

7.  Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.

Authors:  A Faggiano; P Ferolla; F Grimaldi; D Campana; M Manzoni; M V Davì; A Bianchi; R Valcavi; E Papini; D Giuffrida; D Ferone; G Fanciulli; G Arnaldi; G M Franchi; G Francia; G Fasola; L Crinò; A Pontecorvi; P Tomassetti; A Colao
Journal:  J Endocrinol Invest       Date:  2011-11-09       Impact factor: 4.256

Review 8.  Malignant central airway obstruction.

Authors:  Lakshmi Mudambi; Russell Miller; George A Eapen
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

9.  Survival and Predictors of Death for Patients with Bronchopulmonary Carcinoid at a Danish Tertiary NET Centre.

Authors:  Linda Skibsted Kornerup; Gitte Dam; Henning Gronbaek
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 10.  The Diagnosis and Treatment of Bronchopulmonary Carcinoid.

Authors:  Jussuf T Kaifi; Gian Kayser; Juri Ruf; Bernward Passlick
Journal:  Dtsch Arztebl Int       Date:  2015-07-06       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.